It is uncertain that ROS1 rearrangement may represent a potentialnew therapeutic opportunity for now, but biomarker discovery efforts should be continued to develop molecular tumor classification and to improve outcome and management of patients with GBM. This evidence concerns the gene ROS1 and glioblastoma.